JP2011506442A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506442A5
JP2011506442A5 JP2010537957A JP2010537957A JP2011506442A5 JP 2011506442 A5 JP2011506442 A5 JP 2011506442A5 JP 2010537957 A JP2010537957 A JP 2010537957A JP 2010537957 A JP2010537957 A JP 2010537957A JP 2011506442 A5 JP2011506442 A5 JP 2011506442A5
Authority
JP
Japan
Prior art keywords
exendin
formulation
concentration
pharmaceutical formulation
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010537957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/013599 external-priority patent/WO2009075859A2/en
Publication of JP2011506442A publication Critical patent/JP2011506442A/ja
Publication of JP2011506442A5 publication Critical patent/JP2011506442A5/ja
Withdrawn legal-status Critical Current

Links

JP2010537957A 2007-12-11 2008-12-11 インスリン分泌性ペプチド結合体の製剤 Withdrawn JP2011506442A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US734607P 2007-12-11 2007-12-11
US2929508P 2008-02-15 2008-02-15
US20087908P 2008-12-03 2008-12-03
PCT/US2008/013599 WO2009075859A2 (en) 2007-12-11 2008-12-11 Formulation of insulinotropic peptide conjugates

Publications (2)

Publication Number Publication Date
JP2011506442A JP2011506442A (ja) 2011-03-03
JP2011506442A5 true JP2011506442A5 (https=) 2013-06-13

Family

ID=40636823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537957A Withdrawn JP2011506442A (ja) 2007-12-11 2008-12-11 インスリン分泌性ペプチド結合体の製剤

Country Status (6)

Country Link
US (1) US20090186819A1 (https=)
EP (1) EP2231191A2 (https=)
JP (1) JP2011506442A (https=)
CN (1) CN102026666B (https=)
CA (1) CA2708762A1 (https=)
WO (1) WO2009075859A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
JP5643762B2 (ja) * 2008-10-15 2014-12-17 インターシア セラピューティクス，インコーポレイティド 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
CN102597775A (zh) * 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) * 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
EP2538974B1 (en) * 2010-02-24 2018-04-18 Arecor Limited Protein formulations
WO2011109784A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
CN103124793B (zh) * 2010-08-11 2014-12-31 协和梅迪克斯株式会社 糖化血红蛋白的测定方法
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9289516B2 (en) 2011-03-09 2016-03-22 The General Hospital Corporation Imaging beta cell mass
CN102766204B (zh) * 2011-05-05 2014-10-15 天津药物研究院 胰高血糖素样肽-1突变体多肽及其制备方法和其应用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102854325B (zh) * 2011-07-01 2015-01-07 复旦大学 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN102532303A (zh) * 2011-12-22 2012-07-04 江苏弘和药物研发有限公司 聚乙二醇缀合的艾塞那肽的合成及应用
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN103655468B (zh) * 2013-12-02 2015-04-22 无锡和邦生物科技有限公司 一种促胰岛素分泌肽融合蛋白Exendin-4-HSA溶液稳定制剂
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
BR112016023839A8 (pt) * 2014-04-17 2023-04-11 Merck Sharp & Dohme Complexo de tanato de sitagliptina, composição farmacêutica, intermediário farmacêutico, forma de dosagem oral, e, uso de um complexo de tanato de sitagliptina
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
HUE053347T2 (hu) * 2014-11-06 2021-06-28 Xellia Pharmaceuticals Aps Glikopeptid-készítmények
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN109562185A (zh) * 2016-06-02 2019-04-02 赛诺菲 药剂与能够结合葡萄糖感应蛋白的部分的新颖缀合物
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
BR112020013644A2 (pt) 2018-01-03 2020-12-01 Mederis Diabetes, Llc produto de peptídeo ou sal farmaceuticamente aceitável do mesmo para uso no tratamento de síndrome de ovário policístico, um distúrbio renal ou um distúrbio hepático, e, kit.
CN108042794B (zh) * 2018-01-05 2022-01-25 北京博康健基因科技有限公司 重组促胰岛素分泌素的稳定制剂及其制备方法
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
JP7297077B2 (ja) * 2019-04-26 2023-06-23 南京中硼▲聯▼康医▲療▼科技有限公司 Ｂｐａ凍結乾燥製剤及び製造方法
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
MX2022014670A (es) * 2020-05-22 2023-02-13 Hanmi Pharm Ind Co Ltd Formulacion liquida.
CN112237571B (zh) * 2020-10-26 2022-06-07 无锡和邦生物科技有限公司 一种提高艾塞那肽人血清白蛋白融合蛋白稳定性的冻干粉
MX2023006736A (es) * 2020-12-07 2023-08-21 Spitfire Pharma Llc Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr.
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
AU2021409610A1 (en) * 2020-12-24 2023-07-06 Hanmi Pharm. Co., Ltd. Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
CN115819493B (zh) * 2022-11-16 2026-03-13 河北常山生化药业股份有限公司 一种多肽固相合成方法
WO2025006506A1 (en) * 2023-06-26 2025-01-02 AlbuNext, LLC Albumin bound macromolecule tri-agonist activating glp-1/gip/glucagon receptors and methods therefor

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
CA2106314A1 (en) * 1991-04-05 1992-10-06 John P. Burnier Platelet aggregation inhibitors having high specification for gpiibiiia
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK145493D0 (da) * 1993-12-23 1993-12-23 Dako As Antistof
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
DE59712555D1 (de) * 1996-06-05 2006-04-06 Roche Diagnostics Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO1998005351A1 (en) * 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
AU4351897A (en) * 1996-09-16 1998-04-02 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
FR2757973B1 (fr) * 1996-12-27 1999-04-09 Sgs Thomson Microelectronics Processeur de traitement matriciel
EP0996459B1 (en) * 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6723530B1 (en) * 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
ES2178854T3 (es) * 1997-11-07 2003-01-01 Conjuchem Inc Bibliotecas de marcadores de afinidad para albumina de suero humano.
US6437092B1 (en) * 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
US7223725B1 (en) * 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
JP2003522099A (ja) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US20030170250A1 (en) * 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
NZ512663A (en) * 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
DK1143989T3 (da) * 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7144854B1 (en) * 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
CA2363712C (en) * 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
JP4216480B2 (ja) * 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド ウイルス感染の長期持続性融合ペプチドインヒビター
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
USRE40876E1 (en) * 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090841B1 (en) * 2000-05-01 2006-08-15 The Board Of Regents Of The University Of Texas System Use of CD63 inhibitors
ATE397938T1 (de) * 2000-05-19 2008-07-15 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp- 1
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
CN1491233A (zh) * 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
ATE396202T1 (de) * 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7741453B2 (en) * 2001-05-31 2010-06-22 Conjuchem Biotechnologies, Inc. Long lasting fusion peptide inhibitors for HIV infection
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
AU2003239478A1 (en) * 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
EP1684793B1 (en) * 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
JP2007537142A (ja) * 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ アルブミン様物質に結合した新規のｇｌｐ−１類似物
DK2100904T3 (da) * 2004-04-23 2010-11-08 Conjuchem Biotechnologies Inc Fast fase til anvendelse i en fremgangsmåde til rensning af albuminkonjugater
CN112618700A (zh) * 2004-11-12 2021-04-09 诺和诺德公司 促胰岛素肽的稳定制剂
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect

Similar Documents

Publication Publication Date Title
JP2011506442A5 (https=)
JP6685343B2 (ja) 持続型インスリン分泌性ペプチド結合体の液状製剤
CN102026666B (zh) 促胰岛素肽缀合物制剂
TWI630214B (zh) 長效胰島素及胰促泌素肽之液體製劑
CN104884045B (zh) 包括胃泌酸调节素和免疫球蛋白片段的蛋白质缀合物的液体制剂
ES2949553T3 (es) Composición para el tratamiento de la diabetes, que contiene conjugado de análogo de insulina de acción prolongada y conjugado de péptido de secreción de insulina de acción prolongada
WO2011109787A1 (en) Methods of administering insulinotropic peptides
WO2011109784A1 (en) Formulation of insulinotropic peptide conjugates
KR20140015207A (ko) 지속형 인슐린 결합체의 액상 제제
JP6549104B2 (ja) 持続型ヒト成長ホルモン製剤
US10441665B2 (en) Liquid formulation of long acting insulinotropic peptide conjugate
TWI882569B (zh) TACI-Fc融合蛋白液體藥物製劑
CN104870469A (zh) 药物组合物
HK1204565B (en) A liquid formulation of long acting insulinotropic peptide conjugate
BR112015001735B1 (pt) Formulação líquida de conjugado de peptídeo insulinotrópico de ação de longa duração